Osteogenic growth peptideОстеогенный ростовой пептид
Osteogenic growth peptide (OGP) is a 14-amino-acid peptide derived from the C-terminal sequence of histone H4. Bone studies distinguish full-length OGP from its shorter active fragment.
What the studies found
Animal research · 2026
OGP-mimetic hydrogel promoted dental-tissue differentiation in experimental models
- Dental-pulp differentiation
- RUNX2, ALP and DSPP expression increasedHuman cells in culture
- Cell proliferation
- No significant change
- Mineralized tissue
- Increased formation in an ectopic renal-capsule modelEngineered hydrogel; not isolated OGP in patients
An engineered OGP-mimetic hydrogel enhanced osteogenic/odontogenic differentiation markers RUNX2, ALP and DSPP in dental-pulp stem cells, without significantly changing proliferation. It also increased mineralized-tissue formation in an ectopic implantation model. The system was designed to protect its peptide cargo and control release.
Study notes · methods, sources and limitations
Participants or model Human dental-pulp stem-cell cultures and an ectopic renal-capsule implantation model; OGP-mimetic hydrogel.
Important limitations
- The intervention is an engineered OGP-fragment-mimetic hydrogel, not unmodified OGP. Human cells in culture are not treated patients; the implantation model is not a clinical dental-pulp trial.
Biomaterials 338(Pt B) · Journal publication
Computer modeling · 2026
OGP informs a CB2-binding model and design of a different candidate peptide
- Screening
- 56 peptides → 5 candidates
- Pep-5 functional potency
- EC50 6.0 micromolarPep-5 cell assay; NOT an OGP potency estimate
- OGP contribution
- Modeled CB2 allosteric bindingDocking and molecular dynamics, not a clinical experiment
OGP and Pepcan-12 were used to model a proposed allosteric binding site on CB2. Screening 56 peptides yielded five candidates. Pep-5, the best-performing new candidate, inhibited cAMP accumulation with an EC50 of 6.0 micromolar and enhanced the effect of WIN55,212-2 in the cell assay.
Study notes · methods, sources and limitations
Participants or model CB2 receptor docking and molecular dynamics; cell-based functional testing of a newly designed peptide, Pep-5.
Important limitations
- The measured 6.0 micromolar potency belongs to Pep-5, not OGP. OGP binding was computationally modeled. The proposed binding site and new candidate do not establish a treatment effect in people.
Bioorganic & medicinal chemistry 143 · Journal publication
Animal research · 1992
Histone H4-related osteogenic growth peptide (OGP): a novel circulating stimulator of osteoblastic activity.
Synthetic 14-amino-acid OGP increased osteoblast proliferation and alkaline-phosphatase activity in culture and increased bone mass in injected rats.
Study notes · methods, sources and limitations
Participants or model Osteoblast cultures and rats
Important limitations
- Preclinical endpoints do not establish fracture prevention or benefit in people. The full-length peptide must be distinguished from its 10–14 fragment and tissue mixtures.
EMBO Journal. 11(5):1867–1873 · Indexed abstract
About Osteogenic growth peptide
Names in this research collection
OGP · OGP(10–14)
Identity / background source ↗
Research background
An international peptide-research comparator with original osteoblast and rodent studies. Full-length OGP, its active fragment and marrow extracts are distinct research preparations.
- Compound class
- Archival preparation lead
- Research collection
- Peptide bioregulation · editorial grouping
- Institutions in linked studies
- See individual study records
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
No treatment trial in the newly recovered sources
Study methods
Animal and cell experiments; observational serum data
Independent replication
Related reports are not automatically independent evidence
Source access
Original indexed abstracts; full methodological appraisal pending
Safety evidence
Clinical safety, product equivalence and interactions not established by this collection
Open a topic for the evidence assessment.
Findings by study
Computer modeling · 2026
Targeting the putative allosteric site J of cannabinoid receptor type 2 with peptide modulators: From mechanistic investigation to candidate identification
OGP and Pepcan-12 were used to model a proposed allosteric binding site on CB2. Screening 56 peptides yielded five candidates. Pep-5, the best-performing new candidate, inhibited cAMP accumulation with an EC50 of 6.0 micromolar and enhanced the effect of WIN55,212-2 in the cell assay.
Study notes and original source
Targeting the putative allosteric site J of cannabinoid receptor type 2 with peptide modulators: From mechanistic investigation to candidate identification
· Journal publication
Zhang X, Chen Z, Su M · Bioorganic & medicinal chemistry 143
OGP and Pepcan-12 were used to model a proposed allosteric binding site on CB2. Screening 56 peptides yielded five candidates. Pep-5, the best-performing new candidate, inhibited cAMP accumulation with an EC50 of 6.0 micromolar and enhanced the effect of WIN55,212-2 in the cell assay.
Results and tables
Reported findings and study design
OGP and Pepcan-12 were used to model a proposed allosteric binding site on CB2. Screening 56 peptides yielded five candidates. Pep-5, the best-performing new candidate, inhibited cAMP accumulation with an EC50 of 6.0 micromolar and enhanced the effect of WIN55,212-2 in the cell assay.
Population or model CB2 receptor docking and molecular dynamics; cell-based functional testing of a newly designed peptide, Pep-5.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Screening | 56 peptides → 5 candidates | |
| Pep-5 functional potency | EC50 6.0 micromolar | Pep-5 cell assay; NOT an OGP potency estimate |
| OGP contribution | Modeled CB2 allosteric binding | Docking and molecular dynamics, not a clinical experiment |
The measured 6.0 micromolar potency belongs to Pep-5, not OGP. OGP binding was computationally modeled. The proposed binding site and new candidate do not establish a treatment effect in people.
Source for these results ↗ · Reviewed 2026-10-31
- Population / setting
- CB2 receptor docking and molecular dynamics; cell-based functional testing of a newly designed peptide, Pep-5.
- Source reviewed
- Primary publication metadata and indexed abstract checked through Europe PMC on 31 October 2026. No unavailable effect sizes inferred.
Study limitations
- The measured 6.0 micromolar potency belongs to Pep-5, not OGP. OGP binding was computationally modeled. The proposed binding site and new candidate do not establish a treatment effect in people.
Reviewed 2026-10-31.
Animal research · 2026
An OGP binding protein complex-mimicking peptide hydrogel for dental pulp regeneration
An engineered OGP-mimetic hydrogel enhanced osteogenic/odontogenic differentiation markers RUNX2, ALP and DSPP in dental-pulp stem cells, without significantly changing proliferation. It also increased mineralized-tissue formation in an ectopic implantation model. The system was designed to protect its peptide cargo and control release.
Study notes and original source
An OGP binding protein complex-mimicking peptide hydrogel for dental pulp regeneration
· Journal publication
Sha Y, Zhan W, Qin Z, Sun S, Li J, Zong Y, Li M, Jiang F, Liang G, Zhang G · Biomaterials 338(Pt B)
An engineered OGP-mimetic hydrogel enhanced osteogenic/odontogenic differentiation markers RUNX2, ALP and DSPP in dental-pulp stem cells, without significantly changing proliferation. It also increased mineralized-tissue formation in an ectopic implantation model. The system was designed to protect its peptide cargo and control release.
Results and tables
Reported findings and study design
An engineered OGP-mimetic hydrogel enhanced osteogenic/odontogenic differentiation markers RUNX2, ALP and DSPP in dental-pulp stem cells, without significantly changing proliferation. It also increased mineralized-tissue formation in an ectopic implantation model. The system was designed to protect its peptide cargo and control release.
Population or model Human dental-pulp stem-cell cultures and an ectopic renal-capsule implantation model; OGP-mimetic hydrogel.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Dental-pulp differentiation | RUNX2, ALP and DSPP expression increased | Human cells in culture |
| Cell proliferation | No significant change | |
| Mineralized tissue | Increased formation in an ectopic renal-capsule model | Engineered hydrogel; not isolated OGP in patients |
The intervention is an engineered OGP-fragment-mimetic hydrogel, not unmodified OGP. Human cells in culture are not treated patients; the implantation model is not a clinical dental-pulp trial.
Source for these results ↗ · Reviewed 2026-10-31
- Population / setting
- Human dental-pulp stem-cell cultures and an ectopic renal-capsule implantation model; OGP-mimetic hydrogel.
- Source reviewed
- Primary publication metadata and indexed abstract checked through Europe PMC on 31 October 2026. No unavailable effect sizes inferred.
Study limitations
- The intervention is an engineered OGP-fragment-mimetic hydrogel, not unmodified OGP. Human cells in culture are not treated patients; the implantation model is not a clinical dental-pulp trial.
Reviewed 2026-10-31.
Animal research · 1992
Histone H4-related osteogenic growth peptide (OGP): a novel circulating stimulator of osteoblastic activity.
Synthetic 14-amino-acid OGP increased osteoblast proliferation and alkaline-phosphatase activity in culture and increased bone mass in injected rats.
Study notes and original source
Histone H4-related osteogenic growth peptide (OGP): a novel circulating stimulator of osteoblastic activity.
14-amino-acid OGP; not a marrow extract
Format: Journal article · Reviewed: Indexed abstract reviewed
I. Bab, D. Gazit, M. Chorev, A. Muhlrad, A. Shteyer, Z. Greenberg, M. Namdar, A. Kahn · EMBO Journal. 11(5):1867–1873
Synthetic 14-amino-acid OGP increased osteoblast proliferation and alkaline-phosphatase activity in culture and increased bone mass in injected rats.
- Population / setting
- Osteoblast cultures and rats
- Source reviewed
- Original publication metadata and indexed abstract checked; full methods and tables not appraised.
Study limitations
- Preclinical endpoints do not establish fracture prevention or benefit in people.
- The full-length peptide must be distinguished from its 10–14 fragment and tissue mixtures.
Reviewed 2026-10-03.
Animal research · 2022
Osteogenic growth peptide is a potent anti-inflammatory and bone preserving hormone via cannabinoid receptor type 2.
The authors reported bone and inflammatory effects that disappeared after genetic or pharmacological disruption of CB2. Circulating OGP declined with age in the women sampled; this was not a treatment trial.
Study notes and original source
Osteogenic growth peptide is a potent anti-inflammatory and bone preserving hormone via cannabinoid receptor type 2.
OGP experimental preparations; sequence-specific methods require full-text appraisal
Format: Journal article · Reviewed: Indexed abstract reviewed
B. Raphael-Mizrahi, M. Attar-Namdar, M. Chourasia, M. G. Cascio, Y. Gabet, et al. · eLife. 11:e65834
The authors reported bone and inflammatory effects that disappeared after genetic or pharmacological disruption of CB2. Circulating OGP declined with age in the women sampled; this was not a treatment trial.
- Population / setting
- Mouse models, cell assays including human osteoblasts, and observational human serum measurements
- Source reviewed
- Original publication metadata and indexed abstract checked; full methods and tables not appraised.
Study limitations
- Mouse treatment and cultured human cells do not demonstrate human treatment efficacy.
- The human serum association cannot establish causation.
- Full-length OGP and the active fragment must be distinguished in each experimental method.
Reviewed 2026-10-03.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗